Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05148663 · ClinicalTrials.gov registry record
CCM Blood Biomarker Validation Study
A clinical trial, sponsored by Texas Tech University Health Sciences Center, El Paso.
- Terminated
- Registry status
- 12
- Enrollment target
NCT05148663 is a clinical trial that was terminated before completion, run by Texas Tech University Health Sciences Center, El Paso. The registered enrollment target is 12 participants.
The verdict
NCT05148663 was terminated before completion, sponsored by Texas Tech University Health Sciences Center, El Paso.
- TERMINATED
- Registry status
- 12 participants
- Enrollment target
Study Summary
Cerebral cavernous malformations (CCMs), one of the most common microvascular malformations in the capillary beds of the brain, are susceptible to hemorrhagic stroke. As an autosomal dominant disorder with incomplete penetrance, the majority of CCM gene mutation carriers are largely asymptomatic but when symptoms occur, the disease has typically reached the stage of focal hemorrhage with irreversible brain damage. Currently, the invasive neurosurgery removal of CCM lesions is the only treatment option, despite the recurrence of the symptoms after surgery. Therefore, there is a grave need for prognostic/monitoring biomarkers as risk predictors for stroke prevention. The objective of the proposal is to develop a set of blood prognostic/monitoring biomarkers as precise risk indicators for stroke prevention. In this project, the plan is to validate the novel serum biomarkers identified in Ccms animal models and human CCMs patients, and utilize these biomarkers with statistical algorithms for risk prediction of hemorrhagic CCMs. This proposal has been formulated based on recent findings of five serum etiological biomarkers associated with disruption of the Blood-Brain Barrier (BBB), the first step for hemorrhagic CCMs in Ccm mice models. This work will lay the groundwork for larger human trials for final validation and revolutionary potential clinical applications.
Interventions
- DIAGNOSTIC_TEST CCM Hemorrhagic Panel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-01-01 |
| Est. Completion | 2023-08-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05148663
The ClinicalTrials.gov registry entry for NCT05148663 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Tech University Health Sciences Center, El Paso, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CCM Hemorrhagic Panel is the first listed.
NCT05148663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05148663 about?
NCT05148663 is a clinical study titled "CCM Blood Biomarker Validation Study". Cerebral cavernous malformations (CCMs), one of the most common microvascular malformations in the capillary beds of the brain, are susceptible to hemorrhagic stroke. As an autosomal dominant disorder with incomplete penetrance, the majority of CCM gene mutation carriers are largely asymptomatic but...
What is the current status of trial NCT05148663?
This trial is currently terminated. The enrollment target is 12 participants. The study started on 2021-01-01. Estimated completion is 2023-08-29.
What interventions are being tested in trial NCT05148663?
The interventions under investigation include: CCM Hemorrhagic Panel (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05148663?
This trial is sponsored by Texas Tech University Health Sciences Center, El Paso, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.